Exposure to candesartan during the first trimester of pregnancy in type 1 diabetes: experience from the placebo-controlled DIabetic REtinopathy Candesartan Trials

M Porta, J W Hainer, S-O Jansson, A Malm, R Bilous, N Chaturvedi, J H Fuller, Roland Blunch Klein, T Orchard, Hans-Henrik Dyring Parving, A-K Sjølie, DIRECT Study Group

    33 Citations (Scopus)

    Abstract

    The teratogenic consequences of angiotensin-converting enzyme inhibitors angiotensin receptor blockers (ARBs) during the second and third trimesters of pregnancy are well described. However, the consequences of exposure during the first trimester are unclear, especially in diabetes. We report the experience from DIRECT (DIabetic REtinopathy and Candesartan Trials), three placebo-controlled studies designed to examine the effects of an ARB, candesartan, on diabetic retinopathy.
    Original languageEnglish
    JournalDiabetologia
    Volume54
    Issue number6
    Pages (from-to)1298-303
    Number of pages6
    ISSN0012-186X
    DOIs
    Publication statusPublished - 2011

    Keywords

    • Abnormalities, Drug-Induced
    • Adolescent
    • Adult
    • Angiotensin Receptor Antagonists
    • Benzimidazoles
    • Diabetes Mellitus, Type 1
    • Diabetic Retinopathy
    • Female
    • Humans
    • Hypertension
    • Pregnancy
    • Pregnancy Complications, Cardiovascular
    • Pregnancy Outcome
    • Pregnancy Trimester, First
    • Risk Factors
    • Tetrazoles
    • Young Adult

    Fingerprint

    Dive into the research topics of 'Exposure to candesartan during the first trimester of pregnancy in type 1 diabetes: experience from the placebo-controlled DIabetic REtinopathy Candesartan Trials'. Together they form a unique fingerprint.

    Cite this